News
QTTB
5.72
-6.08%
-0.37
Weekly Report: what happened at QTTB last week (0406-0410)?
Weekly Report · 3d ago
Q32 Bio to join Needham Virtual Healthcare Conference fireside chat
Reuters · 04/08 10:59
Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference
PR Newswire · 04/08 10:59
Weekly Report: what happened at QTTB last week (0330-0403)?
Weekly Report · 04/06 09:32
Q32 Bio: Bempikibart Keeps The Alopecia Areata Bull Case Alive
Seeking Alpha · 03/30 12:33
Weekly Report: what happened at QTTB last week (0323-0327)?
Weekly Report · 03/30 09:32
Q32 Bio Launches Flexible $14.2 Million ATM Program
TipRanks · 03/27 22:38
Q32 Bio Files Prospectus To Offer And Sell Common Stock Up To $14.2M Through Cantor
Benzinga · 03/27 21:25
Q32 BIO INC - MAY OFFER AND SELL COMMON STOCK UP TO $14.2 MLN THROUGH CANTOR - SEC FILING
Reuters · 03/27 21:22
Q32 Bio enters $14 million at-the-market equity distribution agreement; Cantor Fitzgerald commission set at 3.0%
Reuters · 03/27 21:16
Best Momentum Stocks to Buy for March 27th
NASDAQ · 03/27 14:15
New Strong Buy Stocks for March 27th
NASDAQ · 03/27 08:35
Weekly Report: what happened at QTTB last week (0316-0320)?
Weekly Report · 03/23 09:30
Q32 Bio (QTTB) Upgraded to Strong Buy: Here's What You Should Know
NASDAQ · 03/19 16:00
Best Momentum Stocks to Buy for March 19th
NASDAQ · 03/19 14:15
New Strong Buy Stocks for March 19th
NASDAQ · 03/19 10:32
Weekly Report: what happened at QTTB last week (0309-0313)?
Weekly Report · 03/16 09:30
Best Momentum Stocks to Buy for March 13th
NASDAQ · 03/13 14:00
Small-Cap healthcare stocks ranked by quant ratings after earnings season
Seeking Alpha · 03/13 13:55
New Strong Buy Stocks for March 13th
NASDAQ · 03/13 09:19
More
Webull provides a variety of real-time QTTB stock news. You can receive the latest news about Q32 BIO INC through multiple platforms. This information may help you make smarter investment decisions.
About QTTB
Q32 Bio Inc. is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing therapies for alopecia areata and other autoimmune and inflammatory diseases. The Company is advancing bempikibart (ADX-914), a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. Additional discovery and earlier development efforts from its complement inhibitor platform include ADX-096, a C3d mAb – CR1 fusion protein with preclinical data supportive of its use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition.